Anti-Mouse CD40 (Clone FGK45) - Purified

Antibody Details

Product Details

Reactivity Species

Mouse

Host Species

Rat

Immunogen

Recombinant Mouse CD40 Fusion Protein

Product Concentration

0.5 mg/ml

Formulation

This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Storage and Handling

This purified antibody is stable when stored at 2-8°C. Do not freeze.

Country of Origin

USA

Shipping

Next Day 2-8°C

RRID

AB_2829585

Applications and Recommended Usage?
Quality Tested by Leinco

FC The suggested concentration for this FGK45 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Clone FGK45 recognizes an epitope on mouse CD40.

Antigen Distribution

CD40 is widely expressed on antigen-presenting cells such as dendritic cells, B cells, macrophages, and monocytes, in addition to non-immune endothelial cells, basal epithelial cells, and a variety of tumors.

Background

CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) - a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy. Blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific for human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus plays a significant part in Alzheimer disease pathogenesis.

Antigen Details

Protein

CD40

Ligand/Receptor

CD154 (CD40L)

PubMed

CD40

NCBI Gene Bank ID

21939

UniProt.org

Information on Uniprot.org

Research Area

Cell Biology

.

Costimulatory Molecules

.

Immunology

.

Neuroscience

.

Neuroscience Cell Markers

References & Citations

1. Grewall, I. S. et al. (1996) Science 73:1864
2. Schonbeck, U. et al. (1997) J. Biol. Chem. 272:19569
3. Armitage, R. J. et al. (1993) J. Immunol. 150:3671
4. Pullen, S. S. et al. (1999) Biochemistry 38:10168

Technical Protocols